The RISK pathway leading to mitochondria and cardioprotection: how everything started

Authors:
Open Access
Publisher website
Google Scholar
Abstract
Ischaemic heart disease, which often manifests clinically as myocardial infarction (MI), remains a major cause of mortality worldwide. Despite the development of effective pre-clinical cardioprotective therapies, clinical translation has been disappointing. Nevertheless, the ‘reperfusion injury salvage kinase’ (RISK) pathway appears to be a promising target for cardioprotection. This pathway is crucial for the induction of cardioprotection by numerous pharmacological and non-pharmacological interventions, such as ischaemic conditioning. An important component of the cardioprotective effects of the RISK pathway involves the prevention of mitochondrial permeability transition pore (MPTP) opening and subsequent cardiac cell death. Here, we will review the historical perspective of the RISK pathway and focus on its interaction with mitochondria in the setting of cardioprotection.
Funding Information
  • British Heart Foundation (PG/18/44/33790, PG/19/51/34493, PG/21/10798, PG/16/85/32471)
  • the Hatter Foundation

This publication has 98 references indexed in Scilit: